Radiation Therapy

The radiation therapy channel covers all aspects of radiation oncology technology. Radiation therapy includes linear accelerators (LINAC), proton therapy, brachytherapy, image guided radiation therapy (IGRT), focused ultrasound, stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), treatment planning systems and tomotherapy.

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge
January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses,...
read more
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
US Prostate Cancer Nuclear Medicine Diagnostics Market Outlook
January 13, 2021 — The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast...
read more
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
MRI Frequently Underestimates Tumor Size in Prostate Cancer
January 11, 2021 — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic...
read more
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
Focused Ultrasound Shows Promise for Parkinson's Disease
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with Parkinson’s...
read more
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
Mirion Technologies Acquires Sun Nuclear Corporation
January 8, 2021 — Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement...
read more
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
RAD Technology Medical Systems to Expand their Patented Modular Building Portfolio
January 4, 2021 — RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular...
read more
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
Brachytherapy Planning and a Speed Revolution in Proton Monte Carlo Dose Computation
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning...
read more
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
C-RAD Receives Order for Proton Cancer Treatment Centers in the U.S.
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy -...
read more
According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Image courtesy of Zeiss

News | Radiation Therapy | December 21, 2020
Single-Dose Radiation Therapy Can Counteract Serious Breast Cancer Treatment Compliance Issues During Pandemic
December 21, 2020 — According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase...
read more
Companies to develop compatibility of Philips’ MR Ingenia 3.0T and 1.5T systems with the InSightec Exablate Neuro platform
News | Focused Ultrasound Therapy | December 18, 2020
Philips and InSightec Partner to Expand Access to MR-guided Focused Ultrasound for Incisionless Neurosurgery
December 18, 2020 — Philips and InSightec, a global healthcare company focused on the therapeutic power of acoustic...
read more
 Fujifilm Medical Systems U.S.A., Inc. announced today that UroPartners, the largest urology practice in Illinois and top five in the nation, has chosen to standardize on the Persona CT computed tomography (CT) system to accelerate their oncology treatment planning capabilities
News | Computed Tomography (CT) | December 17, 2020
Fujifilm Announces CT Partnership with Leading Urology Group UroPartners
December 17, 2020 — Fujifilm Medical Systems U.S.A., Inc. announced that UroPartners, the largest urology practice in ...
read more
Primary liver cancer is on the rise worldwide, largely due to an increase in hepatitis C infections and chronic liver disease

Getty Images

News | Radiation Therapy | December 16, 2020
A First-in-human Clinical Trial Shows Microbubbles Augments Radiation in Liver Cancer Patients
December 16, 2020 — Primary liver cancer is on the rise worldwide, largely due to an increase in hepatitis C infections...
read more
The first MRI-guided radiation therapy system provides real-time view of tumors during radiation treatment
News | Radiation Therapy | December 15, 2020
Hoag Brings Groundbreaking Cancer Treatment Technology to Orange County
December 15, 2020 — Hoag Memorial Hospital Presbyterian became the only hospital in Orange County, and one of the first...
read more
Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according to updated 10-year data from the PRIME II study, presented at the 2020 San Antonio Breast Cancer Symposium

Getty Images

News | Radiation Therapy | December 15, 2020
Omitting Radiation Therapy After Breast-conserving Surgery May Not Impact 10-year Survival Rates
December 15, 2020 — Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy...
read more
A new study finds that significant symptoms in young and Black patients are more likely to be under-recognized

Getty Images

News | Radiation Therapy | December 10, 2020
Physicians Don't Always Recognize Patients' Radiation Therapy Side Effects
December 10, 2020 — Physicians did not recognize side effects from radiation therapy in more than half of breast cancer...
read more
Post-neoadjuvant therapy changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma

Pre-treatment (A-C) and post-treatment (D-F) images after eight cycles of systemic FOLFIRINOX and consolidative chemoradiation. Baseline CA 19-9 was 145 U/ml. Pre-treatment whole body axial fused PET/MRI showed FDG avid lesion in body of pancreas (arrow, A) with SUVmax 7.1 and SUVgluc 8.0. Lesion was hypo-enhancing on axial contrast-enhanced T1-weighted (T1W) MR image (arrow, B) from focused abdominal PET/MRI and on CT (arrow, C). Pre-treatment CT tumor volume was 10.3 cm3. Post-treatment whole body axial fused PET/MRI showed complete metabolic response (arrow D) with SUVmax 1.9 and SUVgluc 1.9. Lesion was indistinct on axial contrast-enhanced T1W MRI (arrow, E) and CT (arrow, F), and there was upstream pancreatic parenchymal atrophy. Post-treatment CT tumor volume was 0.46 cm3. There was normalization of CA 19-9. Relative change in SUVmax (ΔSUVgluc) was -73%, and relative change in SUVgluc (ΔSUVgluc) was -76%. Based on change in tumor size, response was categorized as partial response per RECIST. Relative change in tumor volume (ΔTvol) was -96%. Pathology showed major pathologic response (College of American Pathologists score 1.) Images courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | PET-MRI | December 10, 2020
PET/MRI, CT Metrics Assess Pathologic Response of Pancreas Cancer to Neoadjuvant Therapy
December 10, 2020 — According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR...
read more
A new hybrid X-ray detector developed by the University of Surrey outperforms commercial devices — and could lead to more accurate cancer therapy.
News | X-Ray | December 03, 2020
New Hybrid X-ray Detector Goes Toe-to-toe with State-of-the-art Rivals
December 3, 2020 — A new hybrid X-ray detector developed by the University of Surrey outperforms commercial devices —...
read more
For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Getty Images

News | Prostate Cancer | December 02, 2020
Radiation Therapy Has the Greatest Impact on Patient Finances
December 2, 2020 — For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "...
read more
Infinitt has added a Digital Pathology Solution and a Radiation Therapy PACS to its product offerings
News | Enterprise Imaging | November 19, 2020
Infinitt Highlights Enterprise Imaging Platform with Extensive Line of Diagnostic Capabilities at RSNA 2020
November 19, 2020 — Infinitt North America, a single-source provider of enterprise imaging solutions for healthcare,...
read more
During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
Men with Negative Biopsies During Active Surveillance Have Good Outcomes
November 18, 2020 — Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden...
read more
© Copyright Wainscot Media. All Rights Reserved.